Nanogen Licenses Probe Technology to Quest | GenomeWeb

NEW YORK (GenomeWeb News) – Nanogen has licensed its minor groove binder probe technology to Quest Diagnostics for use in human in vitro diagnostics tests.

Clinical lab firm Quest will pay Nanogen an undisclosed upfront fee and royalties based on sales of products that incorporate the MGB Probe technology.

Nanogen noted that licensing deals for the MGB Probe technology now represents the majority of Nanogen's revenues. It said that it has more than 40 reagent and kit products sold for IVD use usnder the MGB Alert and Q-PCR Alert brands.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.